Inotiv, Inc.
inotiv.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2026 10-Q, filed May 11, 2026. Its latest SEC filing is a 15-12G from Jul 29, 2026.
10-Q for Q2 FY2026, filed May 11, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Provides drug discovery and safety-testing services and sells research animals and diets to pharmaceutical and medical-device companies, researchers, and academic and government organizations.
10-K for FY2025, filed Dec 5, 2025Inotiv is a leading contract research organization (“CRO”) dedicated to providing nonclinical and analytical drug discovery and development…View ↗
Through our DSA segment, we provide discovery and translational sciences and safety assessment services (including nonclinical development…View ↗
Through our RMS segment, we offer access to a wide range of purpose-bred animal research models for basic research and drug discovery and…View ↗
Research Models: Our research models business is comprised of the commercial production and sale of laboratory animals and research models…View ↗
Diet, Bedding and Enrichment: Through our Teklad product line (“Teklad”), RMS produces and sells laboratory animal diet, bedding, and…View ↗
How Did They Make Money?
Research and development clients pay for drug discovery, safety testing and related research services through project fees, often with some payment in advance and other amounts billed at milestones as work proceeds. Clients buy research animals, diets and related products through purchase orders, while some animal care services are billed over the service period.
10-K for FY2025, filed Dec 5, 2025Our DSA contracts typically establish an estimated fee to be paid for a proposed set of services designed in consultation with the client.…View ↗
Our RMS product contracts are typically short-term in nature and based upon purchase orders submitted by clients to satisfy specific…View ↗
The Company generally bills for services on a milestone basis. These contracts represent a single performance obligation and due to the…View ↗
Services provided by the Company include contract breeding, client-owned animal colony care ("contract colony management"), health…View ↗
The RMS segment generates products revenue through the commercial production and sale of research models, diets, bedding, enrichment and…View ↗
-
10-K for FY2025, filed Dec 5, 2025
FY2025 revenue by product or service ↗
$513M
-
10-K for FY2025, filed Dec 5, 2025
$513M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Service
|
45%
FY2022: 37%
|
Service, FY2025
$232.9M Sources
|
|
|
Product
Sold outright
10-K for FY2025, filed Dec 5, 2025 |
55%
FY2022: 63%
|
Product, FY2025
$280.2M Sources
|
Sold outright |
Who Were Their Customers?
Pharmaceutical and biotechnology companies buy research services and products; contract research groups, academic institutions and government organizations buy research models and related offerings. The company promotes services through centralized business development and direct scientist-to-scientist communication.
10-K for FY2025, filed Dec 5, 2025Through our DSA segment, we provide discovery and translational sciences and safety assessment services (including nonclinical development…View ↗
Through our RMS segment, we offer access to a wide range of purpose-bred animal research models for basic research and drug discovery and…View ↗
Research Models: Our research models business is comprised of the commercial production and sale of laboratory animals and research models…View ↗
We promote our services through centralized business development and marketing efforts and scientist-to-scientist communications. We…View ↗
10-K for FY2025, filed Dec 5, 2025
During the fiscal year ended September 30, 2025, one client related to the RMS segment accounted for 16.6% of total revenue. During the…View ↗
Did Revenues Turn Into Profits?
No. It lost $68.6M in FY2025.
10-K for FY2025, filed Dec 5, 2025
−$30.9MView ↗
10-K for FY2025, filed Dec 5, 2025
−$68.6MView ↗
10-K for FY2025, filed Dec 5, 2025
−$27.1MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed May 11, 2026
−$32.5MView ↗
- ▲ +118% (Loss)
- vs −$14.9M in Q2 FY2025
10-Q for Q2 FY2026, filed May 11, 2026
Open tableView ↗
-
Jul 16, 2026
Bankruptcy court confirmed Inotiv’s reorganization plan
The plan cancels existing common shares without a distribution to current equity holders; the company expects to emerge as a private company.
Sources
8-K, filed Jul 16, 2026
On July 14, 2026, the Bankruptcy Court entered the Order (I) Approving Debtors’ Disclosure Statement on a Final Basis and (II) Confirming…View ↗
-
Jun 3, 2026
Inotiv filed for Chapter 11 bankruptcy protection
The company and certain subsidiaries filed voluntary petitions to carry out a prepackaged reorganization plan.
Sources
8-K, filed Jun 3, 2026
Milestones. The Restructuring Support Agreement contains certain milestones (“Milestones”) relating to the progress of the anticipated…View ↗
Grew. Revenue grew 5.7x in 4 years, from $89.6M in FY2021 to $513M in FY2025, about 55% a year.
Loading...
